Regenlab USA Inc. S-1IPO prospectus

Executive Summary

RegenLab USA sells regenerative-medicine kits that prepare patients’ own platelet-rich plasma, primarily through international distributors. FY2025 revenue grew just 1.6% to $49.2M with a $(1.24)M net loss; H1 2026 revenue accelerated 21.0% to $29.3M, but $0.071M net income and distributor-driven cash generation do not resolve its financing pressure. The IPO is unpriced, with share counts and valuation blank, although financial-statement notes anticipate ≈$30M of net proceeds for commercial and development investment. This is a commercialization-and-refinancing investment case: growing U.S. wound-care sales offer upside, but buying requires completed offering terms and a credible solution to imminent debt maturities.

The Offering

• Size and valuation: Gross raise, implied market capitalization, buyers’ ownership stake, revenue multiple and fully diluted share count cannot yet be calculated. The preliminary offering supplies neither a price range nor offered/post-offering share counts; 6,238,266 common shares are outstanding before the IPO.
• Structure and costs: Proceeds go to RegenLab through company share issuance. StoneX Financial is the underwriting representative; the discount is 7%, or 5% for company-introduced investors, plus a 1% expense allowance. The additional-share option covers 15% of the base offering for 30 days. Nasdaq listing under RGNA is a condition of completion.
• Funding plan: Financial-statement notes anticipate ≈$30M net proceeds, not established offering terms. Planned allocations are 60%/$18M to sales and marketing, 10%/$3M to manufacturing equipment, and 30%/$9M to research and regulatory work. The named research allocations total $10M rather than $9M; this inconsistency needs clarification. Management’s at-least-12-month funding outlook depends on proceeds and spending assumptions, while debt repayment is not a specified allocation.
• Dilution and capitalization: Per-share tangible assets, purchase-price dilution and after-IPO cash/equity are blank. “After IPO” would reflect issuance proceeds less offering costs; no quantified bridge is available. Representative warrants cover 3% of shares sold, including additional shares, at 125% of the IPO price, exercisable for 4.5 years beginning 180 days after sales commence.
• Resale restrictions: Existing holders, directors and officers face 180-day lock-ups from closing, subject to exceptions. Some shares otherwise become resale-eligible 90 or 180 days after registration effectiveness; the closing-dependent lock-up prevents computing an expiry date now.

Key Financial Highlights

$M unless stated; annual figures audited, FY2024 restated, interim figures unaudited. All figures are historical, before the IPO.

• Annual margin pressure: New-factory staffing, materials and equipment costs combined with 53% higher research spending to compress profitability. H1 improvement reflects stronger U.S. sales and restrained operating expenses.
• Earnings quality: H1 2026 incurred $2.14M of net other expense, including $1.65M finance expense; a $0.115M tax benefit converted a pretax loss into modest net income. Revenue-linked debt royalties also introduce estimate-driven financing expense.
• Cash-flow quality: H1 OCF included $9.44M from other assets/liabilities, offset partly by $3.78M of payable reductions. MiMedx’s $5M upfront payment supports liquidity, so cash generation should not be extrapolated from earnings.
• Equity deficit: Accumulated losses reached $13.2M at 6/30/2026; correcting previously capitalized research increased the FY2024 accumulated deficit by $6.62M. This is not preferred-stock conversion accounting: $66.2M total liabilities include $21.3M notes payable and $18.7M leases.
• Immediate funding need: The $12.8M working-capital deficit and October 2026 maturity of European Investment Bank Tranche A, carrying $8.32M, exceed available liquidity. Refinancing discussions lacked a binding commitment.

Business Model and Growth Drivers

RegenLab earns primarily from product sales, generally recognized on shipment, using more than 120 distribution agreements across over 90 countries. RegenKit and Cellular Matrix generated ≈90.7% of FY2025 revenue, leaving diversification largely a future opportunity.

• Commercial pivot: H1 U.S. sales rose to $8.9M from $4.7M; wound-care sales reached $3.6M from $0.3M. MiMedx contributed $4.12M, including $0.500M of deferred license fees, or ≈14% of revenue. Its exclusive U.S. wound-kit agreement runs through 12/31/2030, with $5M upfront and up to $5M in sales-linked milestones.
• Expansion strategy: Management targets a company-estimated market exceeding $30B across musculoskeletal care, wounds, aesthetics and women’s health. Three plants provide ≈6M treatments/tubes of annual capacity, but approvals, reimbursement and clinician adoption—not capacity alone—determine growth.
• Regulatory pipeline: Cellular Matrix’s U.S. approval application is progressing through modular submissions; RegenMatrix remains developmental. RegenBMC received U.S. clearance on 5/29/2026. Some studies support clinical benefit, but a 2025 randomized trial found no significant differences in key 12-month outcomes.

Governance and Control

• Concentrated control: Each common share carries one vote. Founder, chairman and chief executive Antonino Turzi owns 98.64% before the IPO; the company expects controlled-company status afterward but does not intend to use its governance exemptions.
• Related-party exposure: At 6/30/2026, an unsecured $2.44M principal-stockholder loan receivable bears 3.24% interest through 2030. A Turzi-controlled distributor generated €1.02M of FY2025 sales, making independent oversight consequential.
• Future dilution: The new incentive plan reserves 10% of closing shares, with annual additions of up to 1% through 2036. This reserve is distinct from granted awards and creates potential dilution beyond underwriting warrants.

Risk Assessment

• Accounting controls: Material weaknesses in staffing, segregation of duties and the formal control environment, alongside the $6.62M research-capitalization correction, increase reporting-reliability risk.
• Going concern: The auditor highlights substantial doubt; $4.83M cash cannot cover the $8.32M October maturity without refinancing or capital.
• Clinical and reimbursement: Mixed evidence, unapproved indications and conditional wound-care coverage can delay adoption or strand development spending.
• Distributor/product concentration: Two products dominate sales, while MiMedx drives incremental growth; partner underperformance could reverse recent momentum.
• Supply and currency: Limited specialized input/sterilization alternatives and unhedged Swiss-franc costs can interrupt production or squeeze margins.
• Control and conflicts: Founder voting dominance and related-party lending reduce minority investors’ influence over capital allocation.
• Intellectual property: Invalidation of a Chinese platelet-rich-plasma/hyaluronic-acid patent illustrates the risk that legal challenges weaken product protection.

Investor Actionables

• Completed terms: Evaluate valuation, buyer ownership, warrant/plan dilution and usable proceeds before committing capital.
• October refinancing: Require a binding repayment or refinancing solution, not advanced discussions alone.
• First public results: Track recurring MiMedx sales excluding license fees, gross-margin recovery and OCF excluding upfront-payment effects; durable improvement would strengthen the investment case.